AU2001281040A1 - Gene silencing using mrna-cdna hybrids - Google Patents

Gene silencing using mrna-cdna hybrids

Info

Publication number
AU2001281040A1
AU2001281040A1 AU2001281040A AU8104001A AU2001281040A1 AU 2001281040 A1 AU2001281040 A1 AU 2001281040A1 AU 2001281040 A AU2001281040 A AU 2001281040A AU 8104001 A AU8104001 A AU 8104001A AU 2001281040 A1 AU2001281040 A1 AU 2001281040A1
Authority
AU
Australia
Prior art keywords
mrna
gene silencing
cdna hybrids
hybrids
cdna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001281040A
Inventor
Cheng-Ming Chuong
Shi-Lung Lin
Randall B. Widelitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Publication of AU2001281040A1 publication Critical patent/AU2001281040A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AU2001281040A 2000-08-02 2001-08-02 Gene silencing using mrna-cdna hybrids Abandoned AU2001281040A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22247900P 2000-08-02 2000-08-02
US60/222,479 2000-08-02
PCT/US2001/024412 WO2002010374A2 (en) 2000-08-02 2001-08-02 Gene silencing using mrna-cdna hybrids

Publications (1)

Publication Number Publication Date
AU2001281040A1 true AU2001281040A1 (en) 2002-02-13

Family

ID=22832389

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001281040A Abandoned AU2001281040A1 (en) 2000-08-02 2001-08-02 Gene silencing using mrna-cdna hybrids

Country Status (3)

Country Link
US (2) US7662791B2 (en)
AU (1) AU2001281040A1 (en)
WO (1) WO2002010374A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080242627A1 (en) * 2000-08-02 2008-10-02 University Of Southern California Novel rna interference methods using dna-rna duplex constructs
US6794141B2 (en) * 2000-12-22 2004-09-21 Arcturus Bioscience, Inc. Nucleic acid amplification
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
WO2003042385A2 (en) * 2001-11-12 2003-05-22 Epiclone, Inc. Gene silencing using sense dna and antisense rna hybrid constructs
ES2401326T3 (en) * 2001-11-21 2013-04-18 Astellas Pharma Inc. Procedure to inhibit gene expression
US20050120414A1 (en) * 2002-01-29 2005-06-02 Paul Diamond Regulation of polynucleic acid activity and expression
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP1442143A4 (en) * 2002-02-20 2005-02-16 Sirna Therapeutics Inc RNA INTERFERENCE MEDIATED INHIBITION OF BCL2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP1485503A4 (en) * 2002-03-15 2005-12-28 Arcturus Bioscience Inc Improved nucleic acid amplification
WO2004078941A2 (en) * 2003-03-06 2004-09-16 Oligo Engine, Inc. Modulation of gene expression using dna-rna hybrids
EP1668158B1 (en) * 2003-08-11 2010-10-20 Georgia State University Research Foundation, Inc. Rna detection and quantitation
DE10360546A1 (en) * 2003-12-22 2005-07-14 Patent-Treuhand-Gesellschaft für elektrische Glühlampen mbH Phosphor and light source with such phosphor
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
DE102004051395A1 (en) 2004-10-21 2006-04-27 Patent-Treuhand-Gesellschaft für elektrische Glühlampen mbH Highly efficient, stable oxynitride phosphor
DE102005059521A1 (en) * 2005-12-13 2007-06-14 Patent-Treuhand-Gesellschaft für elektrische Glühlampen mbH Red emitting phosphor and light source with such a phosphor
DE102006008300A1 (en) 2006-02-22 2007-08-30 Patent-Treuhand-Gesellschaft für elektrische Glühlampen mbH Highly efficient phosphor from oxynitridosilicates with cation, used in white light emitting diodes
DE102006052221A1 (en) 2006-11-06 2008-05-08 Patent-Treuhand-Gesellschaft für elektrische Glühlampen mbH Fluorescent coating for highly loaded lamps with color temperatures less than 2700 Kelvin
JP5554231B2 (en) * 2007-06-13 2014-07-23 コモンウェルス サイエンティフィック アンドインダストリアル リサーチ オーガナイゼーション Modification of avian production traits
AU2012204092B2 (en) * 2007-06-13 2014-04-10 Australian Poultry Crc Pty Ltd Modulating production traits in avians
DE102007035592B4 (en) 2007-07-30 2023-05-04 Osram Gmbh Temperature-stable phosphor, use of a phosphor and method for producing a phosphor
DE102007060199A1 (en) 2007-12-14 2009-06-18 Osram Gesellschaft mit beschränkter Haftung Fluorescent and illumination system with such phosphor
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
MX2015014666A (en) 2013-04-17 2016-03-01 Pfizer N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases.
US10196616B2 (en) 2017-02-15 2019-02-05 The United States Of America, As Represented By The Secretary Of Agriculture Altered avian virus for in-ovo inoculation and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4416988A (en) 1980-12-23 1983-11-22 Harvey Rubin Detection and isolation of enkephalin mRNA using a synthetic oligodeoxynucleotide
US4661450A (en) 1983-05-03 1987-04-28 Molecular Genetics Research And Development Limited Partnership Molecular cloning of RNA using RNA ligase and synthetic oligonucleotides
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US5075216A (en) 1988-09-23 1991-12-24 Cetus Corporation Methods for dna sequencing with thermus aquaticus dna polymerase
US5962271A (en) 1996-01-03 1999-10-05 Cloutech Laboratories, Inc. Methods and compositions for generating full-length cDNA having arbitrary nucleotide sequence at the 3'-end
US5932451A (en) 1997-11-19 1999-08-03 Incyte Pharmaceuticals, Inc. Method for unbiased mRNA amplification
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6197554B1 (en) 1998-11-20 2001-03-06 Shi-Lung Lin Method for generating full-length cDNA library from single cells
US6008048A (en) * 1998-12-04 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of EGR-1 expression
US6066500A (en) * 1999-06-25 2000-05-23 Isis Pharmaceuticals Inc. Antisense modulation of Beta catenin expression
EP1873259B1 (en) * 2000-12-01 2012-01-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediated by 21 and 22nt RNAs
US20040087526A1 (en) 2001-11-12 2004-05-06 Shi-Lung Lin Therapeutically useful compositions of DNA-RNA hybrid duplex constructs
US20050287668A1 (en) 2003-11-04 2005-12-29 Cell Therapeutics, Inc. (Cti) RNA interference compositions and screening methods for the identification of novel genes and biological pathways

Also Published As

Publication number Publication date
WO2002010374A3 (en) 2003-08-07
US20100249212A1 (en) 2010-09-30
US20020137709A1 (en) 2002-09-26
WO2002010374A2 (en) 2002-02-07
US7662791B2 (en) 2010-02-16
US8080652B2 (en) 2011-12-20

Similar Documents

Publication Publication Date Title
AU2001281040A1 (en) Gene silencing using mrna-cdna hybrids
AU3369900A (en) Gene silencing
AU2001291656A1 (en) Gene silencing vector
AU2625501A (en) Compositions and methods for gene silencing
GB9925459D0 (en) Gene silencing
GB2377221B (en) Genetic silencing
AU2002245184A1 (en) Nucleic acid amplification
AU2002367580A1 (en) Tissue-engineered organs
AU5215601A (en) Inflammation-related gene
AU2002220553A1 (en) Bioreactor
AU2001242625A1 (en) Gene sequence
AU2001264247A1 (en) GASC1 gene
AU2001240103A1 (en) Reproduction-specific genes
AU6424701A (en) Gasc1 gene
AU2001278598A1 (en) Methods and means for gene silencing
AU2001247444A1 (en) Erbeta-mediated gene expression
AUPQ749100A0 (en) New epilespy gene
AU2001285743A1 (en) Adipose-related gene
AU2002215389A1 (en) Optimized messenger rna
AU7567101A (en) Gene expression system
AU2001284288A1 (en) Plant resistance gene
AU2001284265A1 (en) Genetic study
AU2001274256A1 (en) Plant resistance gene
AU6871900A (en) Tsg-like gene
AU1870000A (en) Gene therapy-2